AU2016248329A1 - Combination treatments with seribantumab - Google Patents

Combination treatments with seribantumab Download PDF

Info

Publication number
AU2016248329A1
AU2016248329A1 AU2016248329A AU2016248329A AU2016248329A1 AU 2016248329 A1 AU2016248329 A1 AU 2016248329A1 AU 2016248329 A AU2016248329 A AU 2016248329A AU 2016248329 A AU2016248329 A AU 2016248329A AU 2016248329 A1 AU2016248329 A1 AU 2016248329A1
Authority
AU
Australia
Prior art keywords
seribantumab
hrg
nsclc
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016248329A
Other languages
English (en)
Inventor
Bambang ADIWIJAYA
Akos CZIBERE
Gavin Macbeath
Rachel C. Nering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrimack Pharmaceuticals Inc
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of AU2016248329A1 publication Critical patent/AU2016248329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2016248329A 2015-04-17 2016-04-15 Combination treatments with seribantumab Abandoned AU2016248329A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149271P 2015-04-17 2015-04-17
US62/149,271 2015-04-17
PCT/US2016/027933 WO2016168730A1 (en) 2015-04-17 2016-04-15 Combination treatments with seribantumab

Publications (1)

Publication Number Publication Date
AU2016248329A1 true AU2016248329A1 (en) 2017-11-09

Family

ID=55854801

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016248329A Abandoned AU2016248329A1 (en) 2015-04-17 2016-04-15 Combination treatments with seribantumab

Country Status (13)

Country Link
US (1) US20160303232A1 (enExample)
EP (1) EP3283068A1 (enExample)
JP (1) JP2018513155A (enExample)
KR (1) KR20170137886A (enExample)
CN (1) CN107750165A (enExample)
AU (1) AU2016248329A1 (enExample)
CA (1) CA2983008A1 (enExample)
EA (1) EA201792294A1 (enExample)
HK (2) HK1248539A1 (enExample)
IL (1) IL255092A0 (enExample)
MA (1) MA45420A (enExample)
SG (1) SG11201708491PA (enExample)
WO (1) WO2016168730A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017161009A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Dosage and administration of combination therapies comprising targeted antibodies uses and methods of treatment
AU2018211985B2 (en) * 2017-01-26 2025-02-13 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof
JP2021530223A (ja) 2018-07-09 2021-11-11 スロゼン， インコーポレイテッド 組織特異性Ｗｎｔシグナル増強分子及びその使用
WO2022104280A1 (en) 2020-11-16 2022-05-19 Surrozen Operating, Inc. Liver-specific wnt signal enhancing molecules and uses thereof
CN115976196B (zh) * 2022-12-16 2024-12-06 深圳市人民医院 ErbB3作为肺动脉高压生物标志物和治疗靶点的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
EP3042963A1 (en) 2005-06-20 2016-07-13 Advanced Cell Diagnostics, Inc. Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8691771B2 (en) 2010-05-21 2014-04-08 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins for tissue repair
JP2013539453A (ja) * 2010-07-09 2013-10-24 エクセリクシス， インク． 癌の治療のためのキナーゼ阻害物質の組み合わせ
WO2012103341A1 (en) 2011-01-27 2012-08-02 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid stage tumors using anti-erbb3 antibodies
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) * 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
MX2013015333A (es) * 2011-06-30 2014-07-09 Merrimack Pharmaceuticals Inc Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos.
AU2012294326A1 (en) 2011-08-10 2013-03-21 Merrimack Pharmaceuticals, Inc. Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
AU2014324478A1 (en) * 2013-09-30 2016-05-05 Amgen, Inc. Nucleic acid biomarker and use thereof
WO2015100459A2 (en) * 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies

Also Published As

Publication number Publication date
HK1250626A1 (zh) 2019-01-11
WO2016168730A1 (en) 2016-10-20
CA2983008A1 (en) 2016-10-20
US20160303232A1 (en) 2016-10-20
EP3283068A1 (en) 2018-02-21
HK1248539A1 (zh) 2018-10-19
JP2018513155A (ja) 2018-05-24
MA45420A (fr) 2019-05-01
CN107750165A (zh) 2018-03-02
EA201792294A1 (ru) 2018-03-30
SG11201708491PA (en) 2017-11-29
KR20170137886A (ko) 2017-12-13
IL255092A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
Catenacci et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Moehler et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
Choudhury et al. A phase I study investigating AZD8186, a potent and selective inhibitor of PI3Kβ/δ, in patients with advanced solid tumors
US20160303232A1 (en) Combination treatments with seribantumab
Zhou et al. Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
Montero et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
JP2020172487A (ja) トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
US20170202973A1 (en) Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
Bendell et al. A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
AU2017235450A1 (en) Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
KR20200014298A (ko) Her2 양성 암의 치료
Kim et al. Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
Hamberg et al. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial
AU2019350581B2 (en) Methods of treatment of cancer comprising Cdc7 inhibitors
McCleary-Wheeler et al. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer
KR20140063578A (ko) 부인과 암들의 치료를 위해 파크리탁셀과 조합한 항-ｅｒｂｂ３ 항체들
Spencer et al. A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP# 8850
JP2021529179A (ja) ポジオチニブと抗ｈｅｒ１、ｈｅｒ２またはｈｅｒ４抗体との組合せおよびその使用法
Chilimoniuk et al. Molecular methods for increasing the effectiveness of ovarian cancer treatment: A systematic review
WO2012177440A1 (en) Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
Chew et al. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
Lu et al. Efficacy and safety of anti–programmed death-ligand 1 monoclonal antibody socazolimab with carboplatin and Etoposide for extensive-stage SCLC: results from the phase 1b clinical trial
KR20240149422A (ko) 암 치료
JP2024509914A (ja) ニューレグリン１（ｎｒｇ１）遺伝子融合に関連する腫瘍を処置するための抗ｅｒｂｂ３（ｈｅｒ３）モノクローナル抗体の投与量および投与

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period